全球检查室开发测试市场规模、份额、趋势和成长分析报告（2026-2034）

实验室自建检测 (LDT) 市场预计将从 2025 年的 106.8 亿美元成长到 2034 年的 194 亿美元，2026 年至 2034 年的复合年增长率为 6.86%。

随着医疗机构对针对特定患者需求的客製化诊断解决方案的需求不断增长，全球实验室自建检测（LDT）市场持续扩张。 LDT在检测罕见疾病、遗传性疾病和复杂感染疾病发挥着至关重要的作用。其柔软性和可自订性使其在先进的临床检查室中极具价值，尤其是在肿瘤学和个人化医疗领域。

对早期精准疾病诊断日益增长的需求是推动成长要素。癌症、感染疾病和慢性病病例的不断增加促使检查室开发自主研发的检测方案。分子诊断、次世代定序和生物标记鑑定等技术的进步也为市场扩张提供了支持。此外，精准医疗意识的不断提高也促进了实验室自建检测（LDT）在临床决策中的应用。

未来，市场可望在更完善的法规结构和品质标准下发展，以确保可靠性和安全性。人工智慧在诊断领域的应用以及基因组检测的扩展将进一步提高检测的准确性和效率。随着医疗系统优先考虑个人化治疗方案，检查室开发的检测方法很可能仍将是现代诊断服务的重要组成部分。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球检查室开发测试市场：依测试类型划分

• 市场分析、洞察与预测
• 临床生物化学
• 免疫学
• 血液学
• 微生物学
• 分子诊断
• 流式细胞技术
• 组织学/细胞学
• 其他类型的测试

第五章：全球检查室开发与测试市场：按应用领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 遗传学
• 感染疾病
• 自体免疫疾病
• 神经病学
• 精神和行为障碍
• 营养和代谢紊乱
• 其他用途

第六章：全球检查室开发与测试市场：依最终用途划分

• 市场分析、洞察与预测
• 医院检查室
• 诊断中心
• 临床研究机构
• 学术研究机构
• 其他最终用户

第七章 全球检查室开发测试市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • 23andMe Inc
  • Abbott
  • Bio-Rad Laboratories Inc
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • NeoGenomics Laboratories
  • OPKO Health Inc
  • QIAGEN
  • Quest Diagnostics Incorporated

The Laboratory Developed Tests Market size is expected to reach USD 19.40 Billion in 2034 from USD 10.68 Billion (2025) growing at a CAGR of 6.86% during 2026-2034.

The Global Laboratory Developed Tests (LDTs) Market is expanding as healthcare providers seek specialized diagnostic solutions tailored to specific patient needs. LDTs play a critical role in detecting rare diseases, genetic conditions, and complex infections. Their flexibility and customization make them highly valuable in advanced clinical laboratories, particularly in oncology and personalized medicine applications.

Rising demand for early and accurate disease diagnosis is a major growth driver. Increasing cases of cancer, infectious diseases, and chronic conditions have encouraged laboratories to develop in-house testing solutions. Technological advancements in molecular diagnostics, next-generation sequencing, and biomarker identification are also supporting market expansion. Additionally, growing awareness about precision medicine is boosting the adoption of LDTs in clinical decision-making.

In the future, the market is expected to evolve with stronger regulatory frameworks and quality standards to ensure reliability and safety. Integration of artificial intelligence in diagnostics and expansion of genomic testing will further enhance test accuracy and efficiency. As healthcare systems prioritize personalized treatment approaches, laboratory developed tests are likely to remain a vital component of modern diagnostic services.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Clinical biochemistry
• Immunology
• Haematology
• Microbiology
• Molecular diagnostics
• Flow cytometry
• Histology/Cytology
• Other test types

By Application

• Oncology
• Genetics
• Infectious diseases
• Autoimmune disorders
• Neurology
• Mental/Behavioral disorder
• Nutritional & metabolic diseases
• Other applications

By End-use

• Hospital laboratories
• Diagnostic centers
• Clinical research organizations
• Academic and research institutes
• Other end-users

COMPANIES PROFILED

• 23andMe Inc, Abbott, BioRad Laboratories Inc, Eurofins Scientific, F HoffmannLa Roche Ltd, Illumina Inc, NeoGenomics Laboratories, OPKO Health Inc, QIAGEN, Quest Diagnostics Incorporated
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Clinical biochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Haematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Microbiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Molecular diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Flow cytometry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Histology/Cytology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other test types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Genetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Mental/Behavioral disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Nutritional & metabolic diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospital laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical research organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Academic and research institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LABORATORY DEVELOPED TESTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 23andMe Inc
  • 9.2.2 Abbott
  • 9.2.3 Bio-Rad Laboratories Inc
  • 9.2.4 Eurofins Scientific
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 Illumina Inc
  • 9.2.7 NeoGenomics Laboratories
  • 9.2.8 OPKO Health Inc
  • 9.2.9 QIAGEN
  • 9.2.10 Quest Diagnostics Incorporated